PRESS RELEASES

Date	Title
Dec 11, 2017	Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China
Nov 28, 2017	Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
Nov 21, 2017	Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline
Nov 7, 2017	Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress
Oct 16, 2017	Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
Oct 11, 2017	Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018
Aug 9, 2017	Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results
Aug 2, 2017	Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference
May 12, 2017	Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
May 5, 2017	Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com